№ lp_2_3_52460
File format: docx
Character count: 5151
File size: 140 KB
This document is a patient handout detailing the eligibility, treatment process, costs, and additional information for people experiencing a flare-up of mild plaque psoriasis, as part of the Victorian Community Pharmacist Statewide Pilot program.
Year:
2024
Region / City:
Australia
Topic:
Psoriasis Treatment
Document Type:
Patient Handout
Organization:
Victorian Government, Department of Health
Author:
Not specified
Target Audience:
Patients with mild plaque psoriasis
Period of validity:
Not specified
Approval Date:
March 2024
Amendment Date:
Not specified
Cost Information:
Free consultation; medicine costs vary based on Medicare and PBS status
Eligibility:
Adults aged 18 or older with mild plaque psoriasis
Additional Support:
Websites provided for more information
Complaint Process:
Information on complaints available at www.health.vic.gov.au/feedback-and-complaints
Safety Net Information:
Medications not included in PBS Safety Net
Consultation Details:
Private consultation with a pharmacist
Prescription Information:
Medicines under PBS or full price for non-listed items
International Students:
Eligible based on specific countries
Consent Process:
Provided during consultation
Health Advice:
Self-care and lifestyle tips included
Expected Outcome:
Symptoms should improve within 2-4 weeks
What to do if symptoms worsen:
Visit a doctor if no improvement or worsening of condition
Contact:
[email protected]
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2022
Region / City:
Wilmington
Topic:
Historic Preservation
Document Type:
Application Instructions
Organization / Institution:
Historic Wilmington Foundation
Author:
Historic Wilmington Foundation
Target Audience:
Property Owners
Effective Period:
Ongoing
Approval Date:
April 2022
Amendment Date:
N/A
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Note:
Year
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical benefits scheme, biological disease-modifying anti-rheumatic drugs (bDMARDs), chronic plaque psoriasis
Document Type:
Research report
Organization / institution:
Drug utilisation sub-committee (DUSC)
Author:
Not specified
Target Audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / City:
Texas
Theme:
Historic Preservation
Document Type:
Application Form
Organization:
Texas Historical Commission
Author:
Texas Historical Commission
Target Audience:
Cemetery Administrators, Historical Markers Sponsors
Approval Date:
2023-01-01
Modification Date:
2023-01-01
Period of Validity:
Until marker approval
Date of Submission:
2023-01-01
Marker Title:
Historic Texas Cemetery Marker
Marker Type:
HTC Medallion, Name & Date Plaque
Shipping Address:
Required business street address
Approval Process:
Completed HTC designation required
Payment Information:
Non-refundable application fee of $100, with a 45-day payment deadline
Marker Fees:
Subject to change due to material costs
Description:
Application form for requesting a Historic Texas Cemetery marker with Medallion and Name & Date Plaque, requiring prior HTC designation approval and payment process.
Year:
2026
Region / city:
Not specified
Topic:
Guselkumab treatment for pediatric plaque psoriasis
Document type:
Research study
Institution:
Not specified
Author:
Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Bart van Hartingsveldt, Meg Jett, Gigi Jiang, Shu Li, Vikash Sinha, Herta Crauwels, Cynthia M.C. DeKlotz, Amy S. Paller
Target audience:
Healthcare professionals, dermatologists
Study period:
Not specified
Date of approval:
Not specified
Date of revisions:
Not specified
Description:
Phase 3, randomized, placebo-controlled study of Guselkumab for pediatric patients with moderate-to-severe plaque psoriasis.
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical benefits scheme, biological disease-modifying anti-rheumatic drugs (bDMARDs), chronic plaque psoriasis
Document Type:
Research report
Organization / institution:
Drug utilisation sub-committee (DUSC)
Author:
Not specified
Target Audience:
Healthcare professionals, policymakers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Date:
21/01/2026
Organisation:
Bedfordshire Hospitals NHS Foundation Trust
Sites:
Bedford site; Luton site
Department:
Dermatology Department
Legislation:
Freedom of Information Act 2000
Reporting period:
October–December 2025
Definition of new patient:
Patient receiving any of the listed treatments for the first time during the reporting period, including those previously treated in 2024 or earlier years
Treatments listed:
Adalimumab (Humira and biosimilars); Etanercept (Enbrel and biosimilars); Infliximab (Remicade and biosimilars); Ustekinumab (Stelara and biosimilars); Apremilast (Otezla); Bimekizumab (Bimzelx); Brodalumab (Kyntheum); Certolizumab (Cimzia); Deucravacitinib (Sotyktu); Dimethyl Fumarate (Skilarence); Guselkumab (Tremfya); Ixekizumab (Taltz); Risankizumab (Skyrizi); Secukinumab (Cosentyx); Spesolimab (Spevigo); Tildrakizumab (Illumetri)
Data categories:
Total Dermatology Department; Psoriasis
Data format:
Numerical counts, including ranges (1–5)
Intellectual property notice:
Subject to Re-use of Public Sector Information Regulations 2015
Author:
FOI Officer
Year:
2026
Region / city:
Not specified
Topic:
Guselkumab treatment for pediatric plaque psoriasis
Document type:
Research study
Institution:
Not specified
Author:
Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Bart van Hartingsveldt, Meg Jett, Gigi Jiang, Shu Li, Vikash Sinha, Herta Crauwels, Cynthia M.C. DeKlotz, Amy S. Paller
Target audience:
Healthcare professionals, dermatologists
Study period:
Not specified
Date of approval:
Not specified
Date of revisions:
Not specified
Description:
Phase 3, randomized, placebo-controlled study of Guselkumab for pediatric patients with moderate-to-severe plaque psoriasis.
Year:
2025
Region / City:
Ternopil
Theme:
Psoriasis, Nursing, Quality of Life, Chronic Disease
Organization / Institution:
I. Horbachevsky Ternopil National Medical University
Author:
Viktoriya Zhura
Target Audience:
Healthcare professionals, nursing educators, researchers
Period of Action:
2025
Approval Date:
2025
Date of Changes:
-
Year:
Not specified
Region / City:
Not specified
Topic:
Clinical trial design, sample size estimation
Document type:
Educational material, study design guide
Author:
Not specified
Target audience:
Clinical researchers, study designers
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Research field:
Genetic epidemiology
Topic:
Genetic association analysis of psoriasis and psoriatic arthritis
Document type:
Research methods and supplementary materials description
Dataset:
Immunochip dataset
Genotyping centres:
Wellcome Trust Sanger Institute; Centre for Public Health Genomics at the University of Virginia; Arthritis Research UK Centre for Genetics and Genomics at the University of Manchester; University of Queensland Diamantina Institute; Trinity Translational Medicine at the University of Dublin
Genotyping software:
GenomeStudio Data Analysis Software Platform (Genotyping Module v1.8.4)
Quality control tools:
PLINK v1.07; EIGENSOFT v4.2; flashpca
Statistical methods:
Identity-by-descent analysis; principal component analysis; logistic regression; Hardy–Weinberg equilibrium filtering
Genetic markers:
SNPs from Immunochip array
Genomic region of interest:
Major Histocompatibility Complex (MHC)
Genes analyzed:
HLA-C; HLA-B; HLA-A
Phenotypes studied:
Psoriasis; Psoriatic arthritis
Population reference datasets:
HapMap3 CEU; CHB; JPT; YRI
Variables analyzed:
Allele frequency; genotype call rate; heterozygosity; age of disease onset
Associated amino acid position:
Position 45 of HLA-B